Stay updated on Pembrolizumab for Intermediate Risk NMIBC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab for Intermediate Risk NMIBC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab for Intermediate Risk NMIBC Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    Removal of items in the Related topics section, specifically Bladder cancer and MedlinePlus Genetics. This alters the navigation and topic tagging on the page, while the core study information remains unchanged.
    Difference
    0.2%
    Check dated 2026-05-10T09:20:28.000Z thumbnail image
  2. Check
    13 days ago
    Change Detected
    Summary
    Bladder cancer is added as a related topic on the page, and MedlinePlus Genetics is listed under related topics to link the study to broader cancer and genetics resources.
    Difference
    0.2%
    Check dated 2026-05-03T01:44:35.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    The page’s footer/version label was updated to “Revision: v3.5.3,” and a related-topics section entry referencing “Bladder cancer” and “MedlinePlus Genetics” was removed.
    Difference
    0.2%
    Check dated 2026-04-25T18:44:24.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    Added 'Bladder cancer' and related topics including MedlinePlus Genetics, and updated the page revision from v3.5.0 to v3.5.2.
    Difference
    0.2%
    Check dated 2026-04-18T13:40:21.000Z thumbnail image
  5. Check
    35 days ago
    Change Detected
    Difference
    0.2%
    Check dated 2026-04-11T10:53:00.000Z thumbnail image
  6. Check
    42 days ago
    Change Detected
    Summary
    Added 'Bladder cancer' as a related topic and added 'MedlinePlus Genetics' as a related topic.
    Difference
    0.2%
    Check dated 2026-04-04T06:19:00.000Z thumbnail image

Stay in the know with updates to Pembrolizumab for Intermediate Risk NMIBC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for Intermediate Risk NMIBC Clinical Trial page.